Bio-Rad Laboratories
BIO · Life Sciences Tools & Services
$369.95
1.8%Bio-Techne
TECH · Life Sciences Tools & Services
$72.55
0.1%The short version
- Bio-Rad Laboratories is the larger business, with $2.6B of revenue in fiscal 2025 against $1.2B for Bio-Techne, about 2.1 times as much.
- Bio-Rad Laboratories grew revenue faster (0.7%, against −0.4%).
- Bio-Techne kept more of each dollar of sales as operating profit (20.7% operating margin, against 1.8% operating margin).
- Bio-Techne turned more of its sales into free cash flow (21.7% FCF margin, against 14.5% FCF margin).
- Bio-Techne earned a higher return on the capital invested in it (9.2%, against 0.5%).
- Investors pay more for each dollar of Bio-Techne’s earnings: a P/E of 62.5x against 46.3x for Bio-Rad Laboratories.
| Latest fiscal year | BIO · FY25 | TECH · FY26 |
|---|---|---|
| Size | ||
| Market cap | $9.9B | $11.4B |
| Revenue | $2.6B | $1.2B |
| Free cash flow | $375M | $263M |
| Net income | $760M | $182M |
| Growth | ||
| Revenue growth | 0.7% | −0.4% |
| 5-year growth | 0.3% | 5.5% |
| Share count change | −3.3% | −1.7% |
| Profitability | ||
| Gross margin | 51.9% | 65.8% |
| Operating margin | 1.8% | 20.7% |
| Net margin | 29.4% | 15.0% |
| FCF margin | 14.5% | 21.7% |
| Return on capital | 0.5% | 9.2% |
| Return on equity | 10.8% | 9.0% |
| Balance sheet | ||
| Net debt | −$329M | −$64.7M |
| Net debt / EBITDA | −1.6x | −0.2x |
| Dividends and buybacks | $296M | $91.6M |
| Valuation & quality | ||
| P/E | 46.3x | 62.5x |
| Piotroski F-score | 5 | 9 |
FY17
BIO $2.2B
TECH $563M
FY18
BIO $2.3B
TECH $643M
FY19
BIO $2.3B
TECH $714M
FY20
BIO $2.5B
TECH $739M
FY21
BIO $2.9B
TECH $931M
FY22
BIO $2.8B
TECH $1.1B
FY23
BIO $2.7B
TECH $1.1B
FY24
BIO $2.6B
TECH $1.2B
FY25
BIO $2.6B
TECH $1.2B
FY26
BIO —
TECH $1.2B
BIO
TECH
FY17
BIO 5.5%
TECH 21.4%
FY18
BIO −4.5%
TECH 21.2%
FY19
BIO 9.9%
TECH 20.6%
FY20
BIO 16.6%
TECH 21.3%
FY21
BIO 17.1%
TECH 25.5%
FY22
BIO 17.2%
TECH 26.8%
FY23
BIO 12.7%
TECH 26.3%
FY24
BIO 10.5%
TECH 17.8%
FY25
BIO 1.8%
TECH 8.4%
FY26
BIO —
TECH 20.7%
BIO
TECH
FY17
BIO −$7.2M
TECH $129M
FY18
BIO $156M
TECH $149M
FY19
BIO $359M
TECH $156M
FY20
BIO $476M
TECH $153M
FY21
BIO $536M
TECH $308M
FY22
BIO $81.6M
TECH $280M
FY23
BIO $218M
TECH $216M
FY24
BIO $290M
TECH $236M
FY25
BIO $375M
TECH $257M
FY26
BIO —
TECH $263M
BIO
TECH
FY17
BIO 5.0%
TECH 7.8%
FY18
BIO −2.4%
TECH 10.9%
FY19
BIO 4.3%
TECH 8.8%
FY20
BIO 4.8%
TECH 8.3%
FY21
BIO 3.6%
TECH 13.7%
FY22
BIO 3.5%
TECH 15.3%
FY23
BIO 3.1%
TECH 13.2%
FY24
BIO 2.9%
TECH 8.6%
FY25
BIO 0.5%
TECH 3.5%
FY26
BIO —
TECH 9.2%
BIO
TECH
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.